Results
Title

Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma.

Authors

Abeykoon, Jithma P.; Vaxman, Julia; Patel, Sanjay V.; Kumar, Shaji; Malave, Gabriella C.; Young, Kimberly S.; Ailawadhi, Sikander; Larsen, Jeremy T.; Dispenzieri, Angela; Muchtar, Eli; Gonsalves, Wilson I.; Kourelis, Taxiarchis; Leung, Nelson; Warsame, Rahma; Go, Ronald S.; Bergsagel, Leif; Lacy, Martha Q.; Rajkumar, S. Vincent; Gertz, Morie A.; Kapoor, Prashant

Abstract

Summary: Belantamab mafodotin (BLMF) is a B‐cell maturation antigen‐directed antibody‐drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF‐induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity‐related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2–not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

Subjects

OCULAR toxicology; MULTIPLE myeloma; ANTIBODY-drug conjugates; TREATMENT effectiveness; CONFIDENCE intervals

Publication

British Journal of Haematology, 2022, Vol 199, Issue 1, p95

ISSN

0007-1048

Publication type

Academic Journal

DOI

10.1111/bjh.18298